Video Consent Proving an Obstacle in India Trials
In November 2013, India's Drug Controller General required that all clinical trials must record on video a participant's informed consent.
In November 2013, India's Drug Controller General required that all clinical trials must record on video a participant's informed consent, which according to a recent article, is driving recruitment rates down.
Physician investigators report the reasons patients are declining clinical trials because of the video recorded consent. Those reasons include, they believe the videos could be leaked; tampered with or misused. Also, social and religious reasons, as well as poor self image during a sickness. The physicians in the article report ranges between 10%-40% of patients declining to participate in the clinical trial after learning of the video consent requirement.
While some believe the video consent has a noble intent, the questions behind the ethics of not allowing participants the decision to opt-out of the video requirement, as well as the long-term effects on science are being debated.
Read the full story here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
